A new preclinical study reported that GHP-88310, an oral antiviral polymerase inhibitor, blocks measles-like virus transmission in a ferret model. Published in Nature Microbiology, the work showed that when given before or after either direct contact or airborne exposure, the drug prevented viral spread and reduced clinical symptoms. The findings were described as unprecedented for this class because the study directly tested transmission dynamics rather than only treatment outcomes. Researchers including Carolin Lieber of Georgia State University and Richard Plemper’s team at CTAR positioned the results as a potential complement to ring vaccination strategies. With the U.S. reporting a measles resurgence amid waning vaccination rates, an orally administered candidate that shortens the infectious window in animals adds urgency to translational planning.